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Introduction
Natural posttranscriptional regulation of gene expres-
sion involves a variety of conserved mechanisms which 
are dependent upon double-stranded RNA (dsRNA) (see 
for example refs. 1 and 2). In the case of RNA interference 
(RNAi), gene silencing involves long precursor dsRNAs 
which are processed into ~21 nucleotide small interfering 
RNAs (siRNAs) by Dicer, a ribonuclease III (RNase III). Each 
ds siRNA consists of a siRNA guide strand (with antisense 
complementarity to its mRNA target) base-paired with its 
passenger (sense) strand. During RNAi, the nascent ds 
siRNA is loaded onto endoribonuclease Argonaute 2 (Ago2) 
of the  RNA-induced silencing complex (RISC).3–6 Studies 
using reconstituted RISC components indicate that Ago2 
directly binds ds siRNA and nicks the passenger strand of 
the siRNA. Subsequent removal of the nicked passenger 
strand from Ago2 requires the endonuclease activity of 
C3PO (component 3 promoter of RISC).7,8 Thus, the siRNA 
passenger strand is cleaved and removed from the RISC 
complex, leaving the ss siRNA guide strand free to direct 
Ago2-mediated cleavage of its target mRNA. The process is 
highly efficient and operates with exquisite selectivity.
The RNAi process can be recapitulated by introduction 
of synthetic siRNA into cells, or via engineered expression 
of short hairpin RNA (shRNA), an siRNA precursor.9 The 
ability of siRNA to target and inhibit gene expression offers 
a route for development of novel therapeutics where key 
disease-related genes have been identified.10,11 Synthetic 
siRNA can be delivered to cells and tissues in vivo by 
siRNA carriers, including biodegradable nanoparticles 
and lipids.10,11 Chemical modifications to improve synthetic 
siRNA stability and resistance to serum endonucleases are 
continually being sought in order to increase the efficacy 
of siRNA-based drugs.10,11 In our own work, we have previ-
ously developed a bifunctional siRNA construct in which the 
3′ end of the siRNA passenger strand was extended with a 
19nt DNA sequence. The 19 nt DNA extension was origi-
nally designed to function as a PCR primer to enable detec-
tion of the very low levels of siRNA effective for RNAi,12 and 
we have described a protocol applicable for quantification 
of different siRNA sequences via the 3′ 19nt DNA exten-
sion (which is common to each construct).12 We have previ-
ously demonstrated that the modified 3′ 19nt DNA/siRNA 
construct is recoverable following induction of RNAi, and is 
quantifiable down to a molar levels per cell.12 It has been 
proposed that this design may be useful for in vivo studies 
on the uptake, distribution and pharmacokinetics of siRNA 
and for the development of siRNA-based therapeutics.12 In 
addition, the 3′ end of the DNA primer sequence forms a 
stable hairpin structure and confers nuclease resistance 
at normal body temperature.13–17 This 3′-DNA/siRNA con-
struct (initially termed “crook siRNA”) is here referred to as 
 “passenger-3′-DNA/ds siRNA” to reflect the position of the 
19nt DNA extension at the 3′ end of the siRNA  passenger 
strand. The siRNA guide strand sequence of this  3′-DNA/
ds siRNA construct was directed against a viral mRNA 
of the human papillomavirus (HPV), namely HPV E7 
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mRNA. Passenger-3′-DNA/ds E7 siRNA-induced selective 
 knock-down of HPV E7 mRNA in human cervical cancer 
cells grown in culture (SiHa cells).12 HPV E6 and E7 are the 
oncogenic driving force in human cervical cancer and, spe-
cifically, HPV E7 alone is essential for cervical cancer cell 
viability.18 In line with this survival function of HPV E7, it was 
observed that targeting HPV E7 with passenger-3′-DNA/ds 
E7 siRNA-induced apoptosis of SiHa cervical cancer cells.12 
Importantly, the passenger-3′-DNA/ds E7 siRNA had no 
apparent effect when transfected into HPV-negative human 
cells, either noncancerous or cancerous.12 This  indicates 
that the synthetic 3′-DNA/ds siRNA construct does not, by 
itself, induce apoptosis or other form of cell killing. Induction 
of apoptosis in the SiHa cervical cancer cells was therefore 
attributed to the observed silencing of exogenous HPV E7 
by passenger-3′-DNA/ds E7 siRNA.12
It seems remarkable that the precise molecular interactions 
involved in RNAi can accommodate such substantial modifi-
cation of the initiating ds siRNA. Indeed, it was this consid-
eration that originally led us to choose the siRNA passenger 
strand for 3′-DNA extension, the rationale being that the pas-
senger strand might require less structural stringency than 
the guide strand, which determines the sequence-specificity 
of target mRNA cleavage. However, others have subsequently 
reported elegant studies indicating that both passenger and 
guide strands are mechanistically involved in RISC activa-
tion.7,8 In addition, the chemical structure of the siRNA pas-
senger strand appears to be important for the overall process 
of RNAi. Chemical modifications that impair cleavage of the 
passenger strand also impact upon the efficiency of RISC acti-
vation and induction of RNAi.8 We therefore decided to probe 
RNAi induction by synthetic 3′-DNA/ds siRNA constructs in 
more detail (see Supplementary Figure S1). Here, we have 
compared unmodified ds siRNA with the following 3′-DNA/
siRNA constructs: (I) guide-3′-DNA/ds siRNA, (II) passenger-
3′-DNA/ds siRNA, (III) guide-3′-DNA/ss siRNA, and (IV) 
passenger-3′-DNA/ss siRNA (see Figure 1a for schematic).
The chosen cellular target was SIRT1 mRNA. SIRT1 is a 
highly conserved NAD+-dependent deacetylase. SIRT1 func-
tions as an epigenetic regulator and is essential for normal 
embryonic development, differentiation and homeostasis 
(see ref. 19 for a recent review). The broad range of SIRT1 
functions is achieved by targeted de-acetylation of histones, 
and also de-acetylation of regulatory proteins and transcrip-
tion factors, including the tumor suppressor p53.19 Imbalance 
of SIRT1 is implicated in various disease processes, includ-
ing neurodegeneration, diabetes and cancer.19 SIRT1 thus 
represents an important target for the development of novel 
therapeutic agents.
The ability of synthetic 3′-DNA/siRNA constructs to deplete 
SIRT1 expression in human cell lines was assessed at the 
levels of cellular mRNA, protein, and phenotypic outcome. 
Molecular complexing between RISC/SIRT1 mRNA was 
evidenced by coimmunoprecipitation with Ago2, eIF6, and 
C3PO, suggesting that silencing by 3′-DNA/siRNA constructs 
occurs via RNAi and activated RISC rather than a RNase 
H-driven mechanism. The 3′ DNA/siRNA constructs con-
taining the guide strand for SIRT1 mRNA (constructs I–III; 
Figure 1a) induced efficient SIRT1 knock-down and can-
cer-specific apoptosis. As expected,  passenger-3′-DNA/ss 
siRNA, which lacks the SIRT1 guide strand, had no effect. The 
3′-DNA mini-hairpin structure formed by the DNA  extension 
increased siRNA stability in serum and the  advantages of 
3′-DNA/RNA constructs for development of novel  RNA-based 
therapeutics are considered.
Results
Synthetic siRNA constructs were transfected into human 
HCT116 cancer and ARPE19 noncancer cell lines grown 
in culture. A schematic of the four 3′-DNA/SIRT1 siRNA 
 constructs used in this study is shown in Figure 1a. To facili-
tate initial screening for SIRT1 depletion, we exploited the 
cancer-specific survival function of SIRT1. It is established 
that RNAi-mediated silencing of SIRT1 induces apoptosis 
in human cancer cell lines, whereas in noncancer cell lines 
SIRT1 silencing has no apparent effect on cell viability.20,21
Induction of apoptosis in HCT116 cancer cells by  3′-DNA/
SIRT1 siRNA constructs
Early passage human HCT116 cancer cells were monitored 
by phase contrast microscopy following 3′-DNA/siRNA trans-
fections. Apoptosis was assessed by annexin V-labeling with 
FACS analysis (Materials and Methods). Visualization showed 
typical monolayer growth of HCT116 cells at subconfluence 
with a few floating apoptotic cells (Figure 1b, top left-hand 
panel). The remaining upper panels in Figure 1b show the 
cells 48 hours following transfection with unmodified SIRT1 
siRNA or with 3′-DNA/SIRT1 siRNA constructs I–IV, as indi-
cated. The unmodified SIRT1 siRNA-induced massive apopto-
sis of the HCT116 cancer cells within 48 hours of transfection 
(Figure 1b,d). This confirms previous observations on SIRT1 
silencing in HCT116 cells.20 Passenger-3′-DNA/ds SIRT1 
siRNA also induced apoptosis (construct II, Figure 1b,d). 
This is consistent with, and extends, previous results in which 
passenger-3′-DNA/ds HPV E7 siRNA was shown to induce 
apoptosis via selective knock-down of exogenous viral HPV 
E7 mRNA in HPV-positive human cancer cells.12
The novel 3′-DNA/SIRT1 siRNA constructs I and III also 
induced apoptosis when transfected into HCT116 cells 
( Figure 1b,d). Both these constructs, guide-3′-DNA/ds 
SIRT1 siRNA and guide-3′-DNA/ss SIRT1 siRNA, contain 
the siRNA guide strand for SIRT1 mRNA. Their ability to 
induce apoptosis is therefore consistent with SIRT1 silenc-
ing. In contrast, passenger-3′-DNA/ss SIRT1 siRNA (con-
struct IV, Figure 1a), which lacks antisense homology for 
SIRT1 mRNA, had no apparent effect and failed to induce 
apoptosis (Figure 1b,d).
The failure of passenger-3′-DNA/ss SIRT1 siRNA to induce 
apoptosis in HCT116 cancer cells is important. This demon-
strates that the 3′-DNA/siRNA construct is not intrinsically 
cytotoxic, nor does it induce apoptosis by any  stress-related 
mechanism. It follows that the induction of apoptosis by 
passenger-3′-DNA/ds siRNA, by guide-3′-DNA/ds siRNA 
and by guide-3′-DNA/ss siRNA (constructs I–III; Figure 1b,d) 
is attributable to the sequence of the guide strand, which is 
targeted against SIRT1 mRNA. For subsequent experiments, 
passenger-3′-DNA/ss siRNA, which carries the 3′-DNA 
extension but lacks homology for the SIRT1 target mRNA, 
www.moleculartherapy.org/mtna
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was included as a negative control for comparison with the 
three 3′-DNA/siRNA constructs containing the SIRT1 siRNA 
guide strand (Figure 1a; constructs I–III).
Cosilencing Foxo4 rescues HCT116 cells from apoptosis
The apoptotic pathway induced in HCT116 cells by SIRT1 
silencing requires the transcription factor Foxo4.20 RNAi-
mediated cosilencing of Foxo4 together with SIRT1 rescues 
the cells from apoptosis, which is otherwise induced by SIRT1 
depletion alone.20 We next asked if Foxo4 is required for the 
proapoptotic effects induced by 3′-DNA/SIRT1 siRNA con-
structs in HCT116 cells. Cosilencing Foxo4 with the  3′-DNA/
SIRT1 siRNA constructs I–III rescued HCT116 cells from 
apoptosis (Figure 1b, lower panel and Figure 1d). RNAi-
induced silencing of Foxo4 alone, or Foxo4 cosilencing with 
passenger-3′-DNA/ss siRNA (construct IV), had no effect on 
HCT116 cell viability (Figure 1b, lower panel and Figure 1d). 
Thus, the apoptotic phenotype induced by constructs I–III 
was Foxo4 dependent and equivalent to that induced by 
unmodified SIRT1 siRNA (see above).
Figure 1 Phenotypic effects of 3′-DNA/SIRT1 siRNA constructs I–IV on HCT116 cancer cells and ARPE19 noncancer cells. 
(a) Schematical representation of the four different 3′-DNA/SIRT1 siRNA constructs that are used in this study and compared throughout 
to standard unmodified SIRT1 siRNA. I = double-stranded SIRT1 siRNA with a 19 nucleotide “crook” DNA extension on the 3′ end of the 
siRNA guide strand; II = double-stranded SIRT1 siRNA with the 19nt DNA extension on the 3′ end of the siRNA passenger strand; III = 
 single-stranded SIRT1 siRNA (guide strand) with the 19nt DNA extension on the 3′ end of the siRNA guide strand; IV = single-stranded 
SIRT1 siRNA (passenger strand) with the DNA extension on the 3′ end of the siRNA passenger strand (b) Phase contrast micrograph 
images of HCT116 cells 48 hours after transfection with 3′-DNA/SIRT1 siRNA constructs or standard SIRT1 siRNA (upper panel) or 
following cotransfection of cells with Foxo4 siRNA (lower panel) as indicated. Untreated control = (−). (c) Phase contrast images of ARPE19 
cells 72 hours after transfection with the indicated 3′-DNA/SIRT1 siRNA constructs or standard SIRT1 siRNA. (d) Quantification by annexin 
V-labeling of the apoptotic phenotype induced by 3′-DNA/SIRT1 siRNA constructs 48 hours after transfection of HCT116 cells and its rescue 
by Foxo4 cosilencing (left). Apoptotic levels in ARPE19 cells as determined by annexin V-labeling 72 hours after transfection of ARPE19 
cells (right). Background levels of apoptosis are indicated by the dotted line.
I
II
III
IV
5'
5'
5'
5'
5'
5'
3' guide-3'-DNA/ds siRNA
siRNA:
siRNA:
siRNA:
siRNA:
SI
RT
1
SI
RT
1
SI
RT
1 +
 F
ox
o4
I +
 F
ox
o4
II +
 F
ox
o4
III 
+ 
Fo
xo
4
Fo
xo
4
IV
 +
 F
ox
o4
I III IIIII IIIIV IV
An
ne
xi
n 
V-
po
sit
ive
 (%
)
Foxo4 SIRT1 + Foxo4 I + Foxo4 II + Foxo4 III + Foxo4 IV + Foxo4
HCT116
cancer
cells
HCT116
cancer
cells
ARPE19
noncancer
cells
HCT116 cancer cells
15
d
c
b
a
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0
ARPE19 noncancer cells
SIRT1
SIRT1
I II III IV
I II III IV
−
−
− −
passenger-3'-DNA/ds siRNA
Key:
siRNA guide strand
siRNA passenger strand
19nt “crook” DNA extension
passenger-3'-DNA/ss siRNA
guide-3'-DNA/ss siRNA
3'
3'
3'
3'
3'
Molecular Therapy—Nucleic Acids
RNA Interference by 3′-DNA/siRNA Oligonucleotides
Allison and Milner
4
ARPE19 noncancer cells are refractory to 3′-DNA/SIRT1 
siRNA constructs
SIRT1 is known to be required for HCT116 cell viability, but 
SIRT1 is not required for ARPE19 cell viability.20 We now 
demonstrate that in ARPE19 cells, none of the 3′-DNA/SIRT1 
siRNA constructs I–IV induce apoptosis (Figure 1c,d). 
Indeed, no adverse effects on the cells were apparent over a 
period of 72 hours after transfection. This confirms that none 
of the 3′-DNA/SIRT1 siRNA constructs (I–IV; see Figure 1a) 
is intrinsically cytotoxic, as evidenced by transfection into 
human ARPE19 noncancer epithelial cells.
Selective knock-down of SIRT1 mRNA and protein in 
both HCT116 and ARPE19 cells
The above results with HCT116 cells indicate selective 
knock-down of SIRT1 by 3′-DNA/siRNA constructs which 
contain the SIRT1 siRNA guide strand. To confirm this, we 
next assessed SIRT1 mRNA levels following transfection 
with the 3′-DNA/ SIRT1 siRNA constructs I–IV. For both 
HCT116 cells and ARPE19 cells, >80% SIRT1 mRNA knock-
down was observed for each of the three  3′-DNA/siRNA 
constructs containing the SIRT1 siRNA guide strand (con-
structs I–III; Figure 2a,b respectively). In contrast, little if any 
SIRT1 mRNA depletion was observed following transfection 
with passenger-3′-DNA/ss siRNA, which lacks antisense 
homology for SIRT1 mRNA (construct IV;  Figure 2a,b). 
These effects on SIRT1 mRNA levels were mirrored at the 
level of SIRT1 protein (Figure 2c, HCT116 cells; Figure 
2d, ARPE19 cells). We conclude that 3′-DNA/SIRT1 siRNA 
constructs containing the SIRT1 siRNA guide strand induce 
SIRT1 mRNA depletion, with consequent depletion of SIRT1 
protein. Importantly, SIRT1 knock-down is observed in both 
HCT116 cells and ARPE19 cells ( Figure 2). Thus, the lack of 
apoptosis in ARPE19 cells (Figure 1b,d) cannot be explained 
by failure of SIRT1 knock-down in this particular cell line.
Effects on p53 protein levels, phosphorylation, and 
acetylation
In nonstressed cells, p53 protein is present in its latent form 
with a very short half-life. In response to stress, p53 is stabi-
lized by posttranslational modifications, including S15 phos-
phorylation and K382 acetylation. Different permutations of 
p53 modification help couple the p53 stress response with 
the nature of the stress suffered by the cell.22 Downregulation 
of activated p53 involves SIRT1-mediated de-acetylation, 
and this attenuates the p53 stress response.22
Importantly, RNAi can be induced experimentally with-
out activating the p53 response.20,23–25 This is evident in 
Figure 2 Selective knock-down of SIRT1 mRNA and protein by 3′-DNA/SIRT1 siRNA constructs I–III in HCT116 and ARPE19 cells. 
Levels of SIRT1 mRNA and lamin A/C mRNA in (a) HCT116 cells and (b) ARPE19 cells 48 hours after transfection with the indicated 
3′-DNA/SIRT1 siRNA constructs; quantitative RT-PCR data are shown, mean ± SD of four independent mRNA determinations. Immunoblots 
showing the effects of the 3′-DNA/SIRT1 siRNA constructs on SIRT1 protein levels in (c) HCT116 cells and (d) ARPE19 cells. Actin shows 
equivalent total protein loading. Effects on p53 protein and p53 acetylation and phosphorylation at specific sites is also shown (see text for 
details; *= nonspecific band).
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the present study for siRNA-induced knock-down of Foxo4 
in HCT116 cells (Figure 2c), and also for siRNA-induced 
knock-down of lamin A/C in ARPE19 cells (Figure 2d). In both 
cases, cellular p53 protein levels remain low, and no changes 
in phosphorylation at S15P nor acetylation at K382Ac are 
evident. In addition, there is no evidence of p53 activation 
in ARPE19 cells transfected with any of the 3′-DNA/SIRT1 
siRNAs used in this study (constructs I–IV, Figure 2c,d). This 
demonstrates that the 3′-DNA/siRNA construct per se does 
not induce a p53 response.
In contrast to ARPE19 noncancer cells, transfection with 
3′-DNA/siRNAs containing the SIRT1 siRNA guide strand 
(constructs I–III) induced apoptosis in the HCT116 cancer 
cells (see above, Figure 1b,d). This correlated with activa-
tion of the p53 protein, marked by S15 phosphorylation and 
K382 acetylation (Figure 2c). Since p53 is constitutively sup-
pressed by SIRT1 in HCT116 cells,20 this result is consistent 
with targeted SIRT1 silencing by each of the  3′-DNA/siRNA 
constructs I–III. The negative control,  passenger-3′-DNA/
ss siRNA (construct IV), had no effect on p53 protein lev-
els, nor upon p53 posttranslational modifications at S15 and 
K382 (Figure 2c). Thus, activation of p53 following trans-
fection of HCT116 cells with 3′-DNA/siRNAs containing the 
SIRT1 siRNA guide strand is not attributable to a nonspecific 
response to the 3′-DNA/siRNA, but instead reflects selective 
silencing of SIRT1 via the SIRT1 siRNA guide strand.
Overall, the above results indicate that 3′-DNA/SIRT1 siRNA 
constructs that contain a siRNA guide strand can induce selec-
tive knock-down of the target SIRT1 mRNA, together with the 
predicted phenotypic consequences of SIRT1 silencing, the 
latter being dependent upon cellular context (i.e. HCT116 can-
cer cells versus ARPE19 noncancer cells). In contrast, pas-
senger 3′-DNA/SIRT1 ssRNA, which lacks the SIRT1 guide 
strand, is ineffective for SIRT1 mRNA knock-down and also 
fails to induce any SIRT1-associated phenotypic changes 
established for human cells grown in culture.
Ago2 immunoprecipitation pulls down SIRT1 mRNA and 
RISC components C3PO and eIF6
The above results indicate that 3′-DNA/SIRT1 siRNA con-
structs containing the SIRT1 guide strand are competent 
for endogenous gene silencing via selective SIRT1 mRNA 
depletion in human cells. We next asked if activated RISC 
is involved in 3′-DNA/SIRT1 siRNA-mediated depletion of 
SIRT1 mRNA. For this purpose, we immunoprecipitated 
Ago2, a major component of RISC, and probed for coim-
munoprecipitating SIRT1 mRNA (Materials and Methods). 
We reasoned that any association of SIRT1 mRNA with 
Ago2 would be indicative of activated RISC. The site of 
mRNA cleavage is determined by the siRNA guide strand 
sequence, in this case located in exon 8 of SIRT1 mRNA 
(nts 1550–1568, see Materials and Methods). The quantifi-
cation of SIRT1 mRNA employed qPCR primers located on 
either side of the siRNA guide sequence (nts 1401–1421 and 
 1704-1684 respectively, see Materials and Methods) and 
therefore report on intact, uncleaved SIRT1 mRNA. Since 
complexing between Ago2 and target mRNA is a transient 
association, prior to mRNA cleavage and degradation, it was 
predicted that the recovery of full-length SIRT1 mRNA would 
be very low. Nonetheless, SIRT1 mRNA was detectable in 
complex with Ago2, and the levels were statistically signifi-
cant ( Figure 3a; P < 0.005). Moreover, the pull-down of full-
length SIRT1 mRNA was six- to eightfold greater following 
transfection with constructs I–III (which induce SIRT1 mRNA 
degradation), compared with construct IV (inactive for induc-
tion of SIRT1 mRNA degradation) (Figures 2 and 4). These 
results are consistent with transient association of  full-length 
SIRT1 mRNA with activated RISC in HCT116 cells trans-
fected with 3′-DNA/SIRT1 siRNA constructs containing the 
SIRT1 guide sequence.
The observed association of SIRT1 mRNA with Ago2 indi-
cates its recognition by 3′-DNA/SIRT1 siRNA-activated RISC. 
In further support of this, we also detected C3PO, another 
component of RISC (see Introduction) and eIF6 in the same 
samples (Figure 3b). The eIF6 protein is known to associate 
with activated RISC and is required for RNAi-mediated regu-
lation of gene expression in human cells.26
 Overall, the above 
results indicate that 3′-DNA/SIRT1 siRNA constructs I–III can 
enter the RISC complex via Ago2 and direct  RNAi-mediated 
depletion of SIRT1 mRNA. Thus, despite their abnormal 
3′-molecular structure, 3′-DNA/SIRT1 siRNA constructs 
appear able to induce RNAi via activating the RISC complex 
and selectively targeting SIRT1 mRNA via the siRNA guide 
strand and Ago2 complexes.
Evidence for siRNA-induced silencing versus RNase 
H-mediated silencing
In the above experiments, we cannot formally exclude 
the involvement of RNase H in the observed depletion of 
SIRT1 mRNA. In order to investigate this further, we com-
pared the depletion of SIRT1 mRNA with the depletion of 
 SIRT1-∆Exon8 mRNA, a newly discovered splice variant 
of SIRT1 which is expressed in HCT116 cells.27 The ratio-
nale underlying this experiment arises from the observation 
that the RNase H-driven antisense mechanism targets both 
 pre-mRNA and mRNA.28 RNase H is thus predicted to silence 
all mRNA splice variants of a target gene via depletion of 
the precursor  pre-mRNA. In contrast to RNase H, siRNA-
induced silencing by RNA interference is specific for the 
mRNA target, and nuclear pre-mRNA remains intact.28 Thus, 
for  siRNA-induced silencing the pre-mRNA and any mRNA 
splice variants which lack the siRNA target sequence should 
be unaffected. From this, we predicted that  RNAi-induced 
silencing of SIRT1 should be selective for SIRT1 full-length 
mRNA over the SIRT1-∆Exon8 splice variant, since the 
siRNA target sequence lies within exon 8 of SIRT1 mRNA.27 
The SIRT1-∆Exon8 splice variant lacks exon 8 and hence 
also lacks the siRNA target sequence.27
Using PCR primers that distinguish between SIRT1 
 full-length mRNA and SIRT1-∆Exon8 splice variant mRNA, 
we show selective depletion of SIRT1 full-length mRNA with 
little, if any effect on SIRT1-∆Exon8 splice variant mRNA 
(Figure 3c; 3′-DNA/siRNA constructs I–III). As expected 
construct IV, which lacks SIRT1 antisense sequence homol-
ogy, had no effect on either mRNA species (Figure 3c). 
We conclude that 3′-DNA/SIRT1 siRNA constructs I–III 
selectively target full-length SIRT1 mRNA, without effect on 
SIRT1-∆Exon8 splice variant mRNA. The SIRT1-∆Exon8 
splice variant mRNA is nonetheless susceptible to RNAi, and 
can be selectively depleted by an siRNA targeted against 
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the junctional sequence of this splice variant27 (see also 
Figure 3c). Overall, these results argue against involve-
ment of an RNase H-driven mechanism accounting for the 
observed phenotypes and depletion of SIRT1 mRNA in cells 
transfected with 3′-DNA/SIRT1 siRNA constructs I–III (Fig-
ures 1–5). Thus, we conclude that the observed depletion 
of SIRT1 mRNA (Figures 2–4) is most likely effected by 
 siRNA-induced, RISC-mediated RNAi.
Dose responses for SIRT1 mRNA knock-down by  3′-DNA/
SIRT1 siRNA constructs
We next compared the efficacy of SIRT1 mRNA knock-down 
by each of the different 3′-DNA/SIRT1 siRNA constructs rela-
tive to each other, and also relative to unmodified ds SIRT1 
siRNA. Twofold dilution series from 100 nmol/l to 195 pmol/l 
for each construct were performed in HCT116 cells with quan-
titative PCR at each dilution point to determine SIRT1 mRNA 
levels. Lamin A/C mRNA was quantitated as control. All the 
3′-DNA/SIRT1 siRNA constructs containing the SIRT1 siRNA 
guide strand gave around 90% SIRT1 mRNA knock-down at 
100 nmol/l (constructs I–III; Figure 4). The IC50s for unmodi-
fied SIRT1 siRNA and for guide-3′-DNA/ds SIRT1 siRNA (con-
struct I) were both less than 0.195 nmol/l.  Passenger-3′-DNA/
ds SIRT1 siRNA (construct II) and  guide-3′-DNA/ss SIRT1 
siRNA (construct III) gave IC50s of 0.495 nmol/l and 3.2 nmol/l 
respectively. As expected, passenger-3′-DNA/ss siRNA (con-
struct IV), which carries the 3′-DNA extension but lacks SIRT1 
antisense homology, failed to deplete SIRT1 mRNA (Figure 4).
Enhanced stability in serum of 3′-DNA/ds siRNA 
constructs
The above results demonstrate that the efficacy of 
 guide-3′-DNA/ds SIRT1 siRNA (construct I) is equivalent to 
unmodified SIRT1 siRNA for the targeted depletion of SIRT1 
mRNA (Figure 4). For passenger-3′-DNA/ds SIRT1 siRNA 
(construct II) and guide-3′-DNA/ss SIRT1 siRNA (construct 
III), IC50s were in the low or subnanomolar range.
To ask if the 3′-DNA/SIRT1 siRNA constructs have any 
advantage over unmodified SIRT1 siRNA, we next compared 
susceptibility to nuclease attack. In HCT116 cancer cells, the 
selective depletion of SIRT1 by SIRT1 siRNA or by  3′-DNA/
SIRT1 siRNA constructs I–III resulted in apoptotic cell death 
within 48 hours of siRNA transfection (Figures 1 and 2). This 
was exploited here by asking whether unmodified SIRT1 
siRNA or the 3′-DNA/SIRT1 siRNA constructs retain their 
RNAi activity and are still able to induce apoptosis if preincu-
bated in 5% serum for 16 hours prior to cell transfection (Fig-
ure 5a). Serum is rich in both DNA and RNA nucleases, and 
we anticipated that the proapoptotic activity of unmodified 
SIRT1 siRNA in HCT116 cells (Figure 1) may be partially or 
completely destroyed by preincubation in cell culture medium 
containing 5% serum. Indeed, this proved to be the case, with 
levels of apoptosis similar to those observed for the untreated 
controls (Figure 5b,c; see also Figure 1d). In contrast to 
unmodified SIRT1 siRNA, the guide-3′-DNA/ds SIRT1 siRNA 
construct (construct I) proved to be resistant to inactivation by 
serum, as indicated by its ability to induce apoptotic cell kill-
ing of HCT116 cancer cells at similar levels with and without 
serum preincubation (Figure 5b,c; see also Figure 1d). The 
passenger-3′-DNA/ds SIRT1 siRNA construct (construct II) 
also appeared to be resistant to serum inactivation as it also 
retained its ability to induce apoptosis in the HCT116 can-
cer cells (Figure 5c) following serum preincubation and at a 
similar level as without serum preincubation (see Figure 1d). 
Figure 3 Coimmunoprecipitation of endogenous SIRT1 
mRNA with Ago2 protein in HCT116 cells transfected with 
3′-DNA/SIRT1 siRNA constructs. (a) Levels of SIRT1 mRNA 
immunoprecipitated with Ago2 antibody or normal mouse IgG 
control antibody. Immunoprecipitated SIRT1 mRNA levels are 
expressed as a percentage of the input SIRT1 mRNA levels. 
HCT116 cell extracts for the immunoprecipitations were prepared 
24 hours after transfection with the indicated 3′-DNA/SIRT1 siRNA 
constructs (see Materials and Methods). (b) Immunoblots showing 
coimmunoprecipitation of C3PO and eIF6 with Ago2 in cells 
transfected with 3′-DNA/SIRT1 siRNA constructs. eIF6 (arrowed) 
runs just ahead of IgG light chain (indicated). (c) Levels of full-length 
SIRT1 mRNA and splice variant SIRT1-∆Exon8 mRNA in HCT116 
cells 48 hours after transfection with the indicated siRNAs or  3′-DNA/
SIRT1 siRNA constructs; quantitative RT-PCR data are shown, 
mean ± SD of four independent mRNA determinations.
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In contrast, guide-3′-DNA/ss SIRT1 siRNA construct (con-
struct III) that was preincubated in 5% serum had lost its abil-
ity to induce apoptosis in HCT116 cancer cells (Figure 5c, 
see also Figure 1d). This suggests that resistance to serum 
nucleases conferred by the 19nt DNA extension also requires 
the double-stranded RNA structure of the siRNA.
The 19nt DNA extension on these constructs forms a 
nuclease-resistant mini-hairpin structure at its 3′ end.13–17 To 
determine whether this mini-hairpin structure is important for 
the resistance conferred by the 19nt DNA extension, a differ-
ent 19nt DNA extension was tested (see Materials and Meth-
ods) that is identical to the original except for the inversion of 
two bases which make it unable to form a mini-hairpin struc-
ture.17 This alternative 19 nt DNA extension was added to 3′ 
end of the guide strand of ds SIRT1 siRNA (guide-3′-DNA/ds 
SIRT1 siRNA construct Im). As expected, construct Im induced 
apoptosis in the HCT116 cancer cells, consistent with SIRT1 
depletion, but induction of apoptosis was largely abolished if 
the construct was preincubated in serum (Figure 5c). This 
indicates that it is the mini-hairpin structure of the DNA exten-
sion that confers protection of the siRNA to nuclease attack 
and that any 19nt DNA extension will not suffice.
We assume that this DNA extension can provide similar 
nuclease protection to any siRNA. To test this assumption, 
we chose a second endogenous cellular target for depletion 
by RNAi. The second target chosen was the c-Jun N-terminal 
kinase JNK2 as we have previously shown that its depletion by 
RNAi also induces apoptosis in HCT116 cancer cells.25 This 
enabled the effects of serum upon the stability of the siRNA 
to be easily screened by quantification of levels of apopto-
sis induced as for SIRT1 siRNA. JNK2 siRNA induced higher 
levels of apoptosis in the HCT116 cancer cells than SIRT1 
depletion consistent with previous studies25 (Figure 5d) but 
following preincubation in serum the ability of JNK2 siRNA to 
induce apoptosis was lost. In contrast, guide-3′-DNA/ds JNK2 
siRNA (JNK2 construct I) induced similar levels of apoptosis 
with and without serum preincubation (Figure 5d, JNK2 I).
The susceptibility of the various 3′-DNA/siRNA constructs 
and unmodified siRNAs to degradation by serum nucleases 
was also analyzed by their direct visualization on agarose 
gels following incubation for 16 hours in either 5% serum or 
no serum (Figure 5a,e,f, see Materials and Methods). siRNAs 
targeted against SIRT1, JNK2, and HPV E7 were employed 
for this study. Incubation with 5% serum resulted in significant 
degradation of unmodified SIRT1 siRNA whereas 3′-DNA/ds 
SIRT1 siRNA constructs I and II appeared unaffected (Figure 
5e). These results correlate with the apparent loss of RNAi 
activity by SIRT1 siRNA following serum preincubation and 
retention of activity by constructs I and II, as indicated by 
their abilities to still induce apoptosis in HCT116 cells (Figure 
5b,c). Similar increased protection from degradation was also 
provided by the addition of the 19nt DNA extension to JNK2 
siRNA or E7 siRNA (Figure 5f). The importance of the 3′ mini-
hairpin structure formed by the DNA extension is indicated 
by the addition of a different 19nt DNA extension to SIRT1 
siRNA which offered less protection from degradation (Fig-
ure 5f, compare construct I and Im).  3′-DNA/single stranded 
SIRT1 siRNA construct III was unable to induce apoptosis 
following serum incubation (Figure 5c), correlating with sig-
nificant levels of degradation (Figure 5e). This indicates that 
the double-stranded RNA structure is required in addition to 
the 3′ DNA extension to protect the siRNA moiety from attack. 
Addition of the DNA extension to single-stranded siRNA did 
result in less degradation, however, than for unmodified sin-
gle-stranded siRNA (Figure 5e).
In principle, this 19 nt DNA extension with its mini-hairpin 
structure can be added to any double-stranded siRNA to pro-
vide increased protection from nucleases, as indicated here 
for SIRT1 siRNA, JNK2 siRNA and HPV E7 siRNA. Future 
studies will address this further and, in particular, ask whether 
this 3′ 19nt DNA extension with its mini-hairpin structure is 
able to stabilize therapeutic siRNAs in vivo.
Discussion
In this work, we have employed SIRT1 mRNA as an endog-
enous mRNA target for testing selective gene silencing by 
synthetic 3′-DNA/siRNA constructs transfected into human 
cells in vitro. SIRT1 is an NAD+-dependent deacetylase.19 
Following cellular stress, SIRT1 downregulates the p53 
stress response by de-acetylating the p53 protein at K382.22 
Figure 4 Dose responses for SIRT1 mRNA knock-down by SIRT1 siRNA and 3′-DNA/SIRT1 siRNA constructs. SIRT1 mRNA levels 
in HCT116 cells 48 hours after transfection with indicated concentrations of the 3′-DNA/SIRT1 siRNA constructs (100 nmol/l to 195 pmol/l, 
twofold dilution series). SIRT1 mRNA knock-down by standard SIRT1 siRNA was also assessed for comparison of efficacy. mRNA levels 
determined by quantitative RT-PCR; mean ± SD of four independent mRNA determinations. The SIRT1 mRNA results were normalized to 
lamin A/C mRNA in each individual sample.
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In addition, SIRT1 can act as a cancer-specific survival factor 
and is essential for the viability of many human cancer cell 
lines when grown in culture.20 Different 3′-DNA/SIRT1 siRNA 
constructs were assessed as follows: (i) for the selective 
depletion of SIRT1 mRNA and SIRT1 protein following trans-
fection into noncancer (ARPE19) and cancer (HCT116) cells; 
(ii) for the selective killing of cancer versus noncancer cells; 
and (iii) for knock-on effects of SIRT1 depletion at the level of 
p53 acetylation in HCT116 cancer cells, which require SIRT1 
in order to maintain constitutive de-acetylation of p53 under 
normal conditions of cell culture.20 The results indicate highly 
selective targeting and silencing of SIRT1 by the  3′-DNA/SIRT1 
siRNA constructs which contain the SIRT1 guide strand 
(constructs I–III; Figures 1–3; and Results section). In con-
trast, passenger-3′-DNA/ss siRNA, which carries the 3′-DNA 
extension but lacks SIRT1 antisense homology, had no effect 
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Figure 5 Comparison of the susceptibility of unmodified siRNAs and 3′-DNA/siRNA constructs to degradation by serum nucleases. 
(a) Schematic indicating the dual experimental approach used to assess the stability of unmodified siRNAs and 3′-DNA/siRNA constructs 
in serum. Analysis of the phenotypic effect 48 hours after transfection provides a readout of whether RNAi functionality is retained or lost. 
Visualization by gel electrophoresis allows levels of degradation of the siRNAs or constructs to be directly compared. (b) Phase contrast 
images of HCT116 cells 48 hours after transfection with serum-preincubated SIRT1 siRNA or serum-preincubated 3′-DNA/SIRT1 siRNA 
construct I. (c) Quantification by annexin V-labeling of apoptosis induced by SIRT1 siRNA and 3′-DNA/SIRT1 siRNA constructs I–III after 16 
hours incubation in 5% serum prior to transfection. Apoptotic levels of HCT116 cells were determined 48 hours after transfection. Mean ± 
SD of three independent experiments. Induction of apoptosis by a novel 3′-DNA/SIRT1 siRNA construct that has a different 3′ 19 nucleotide 
DNA extension on the guide strand (Im) was also tested, both with no serum preincubation (−) and after serum preincubation (+). (d) Levels of 
apoptosis induced in HCT116 cells 48 hours after transfection with unmodified JNK2 siRNA or 3′-DNA/JNK2 siRNA construct I (JNK2 I; see 
Materials and Methods). The effects of no preincubation in serum (−) and 16 hours preincubation in 5% serum (+) are compared. The effects 
of transfection of 3′-DNA/E7 siRNA construct I (E7 I; see Materials and Methods) are also shown (no serum preincubation), which failed to 
induce apoptosis, as expected since HCT116 cells do not express HPV E7 mRNA (see also ref. 12). (e) Gel electrophoresis analysis of SIRT1 
siRNA and 3′-DNA/SIRT1 siRNA constructs I–IV following incubation of equimolar amounts in no serum (−) or 5% serum (+) for 16 hours. 
(f) Effect of 16 hours incubation in no serum (−) or 5% serum (+) on levels of the indicated unmodified siRNAs or 3′-DNA/siRNA constructs. 
The stability of 3′-DNA/SIRT1 siRNA construct I and that of 3′-DNA/SIRT1 siRNA construct Im which differs only in the sequence of the 19 
nucleotide DNA extension were compared. Unmodified JNK2 siRNA versus 3′-DNA/JNK2 siRNA construct I (JNK2 I); unmodified E7 siRNA 
versus 3′-DNA/E7 siRNA constructs I and II (E7 I; E7 II; see Materials and Methods).
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at any level. Overall these biochemical and phenotypic obser-
vations are consistent with the induction of RNA interference 
via synthetic 3′-DNA/SIRT1 siRNAs containing the SIRT1 
guide strand.
Central to the process of RNA interference is RISC, a 
 multi-protein complex within which RNA processing occurs. 
The conversion of pre-RISC (containing Ago2 loaded with ds 
siRNA) to activated RISC requires the slicer activity of Ago2 to 
cleave the siRNA passenger strand. This is followed by further 
cleavage and clearance of the passenger strand by endonu-
clease C3PO (Introduction). C3PO is itself composed of two 
TRAX and six translin subunits. These assemble into an asym-
metric structure with specific residues positioned at the atomic 
level (i) for binding ssRNA and (ii) for nuclease activity (see 
ref. 8 for details). The interaction between Ago2 and siRNA 
is believed to be highly dynamic with large conformational 
shifts in both components.29–32 This dynamic interplay is likely 
to include C3PO subunits as well. Such considerations may 
explain why 2′-O-methylation of siRNA can interfere with pas-
senger strand cleavage by C3PO, and hence with activation 
of RISC.8 They may also explain the aberrant mRNA cleavage 
observed when cells are treated with ssRNA (guide strand) 
modified with 2′F-ribose coupled with 5′-end phosphorylation.33
Given the molecular precision and interactions which 
operate during RISC activation and target mRNA degra-
dation (outlined above), it seems remarkable that the initi-
ating siRNA can accommodate a 3′ 19 nt DNA extension 
containing an intrinsic hairpin structure (see above). In 
theory, this novel 3′-DNA/siRNA construct may operate via 
a  RISC-independent mechanism, possibly via direct mRNA 
association or perturbation of other RNA processing machin-
ery. However, our present results indicate that 3′-DNA/SIRT1 
siRNA constructs containing the SIRT1 siRNA guide strand 
are able (i) to induce targeted mRNA knock-down and (ii) 
to associate with Ago2 and other components of the RISC 
complex, such as C3PO and eIF6. These results support 
the notion that 3′-DNA/siRNA constructs are competent for 
selective gene silencing via RNAi-mediated mRNA deple-
tion. Our results argue against a RNase H-driven antisense 
mechanism as this targets both pre-mRNA and mRNA,28 and 
the 3′-DNA/SIRT1 siRNA constructs had no effect on mRNA 
expression of the SIRT1-∆Exon8 splice variant (Figure 3c). 
RNAi-induced silencing of SIRT1 is selective for SIRT1 
 full-length mRNA over the SIRT1-Exon∆8 splice variant 
since the siRNA target sequence lies within exon 8 of SIRT1 
mRNA.27 The SIRT1-Exon∆8 splice variant lacks exon 8 and 
hence also lacks the siRNA target sequence.27
We believe that 3′-DNA/ds siRNA constructs may prove 
useful for studying the molecular mechanism of RISC acti-
vation in mammalian cells. Our work shows that the 3′-DNA 
extension can be employed as a differential marker on either 
passenger or guide RNA strands, with little detrimental effect 
on RISC activation. Thus, it may be possible to employ differ-
ential labeling of each siRNA strand for detailed analysis of the 
functional interplay between RISC components Ago2, C3PO, 
and eIF6 during the initiation and process of RNA interference.
We show that both guide and passenger strands of 
the siRNA can accommodate the 3′-DNA extension with 
remarkably little reduction in RNAi efficacy (Figure 4). Even 
 single-stranded guide-3′-DNA/SIRT1 siRNA gave good 
SIRT1 mRNA knock-down, with an IC50 of 3.2 nmol/l. We 
further show that this 3′ 19 nt DNA extension helps to protect 
the siRNA from degradation by serum nucleases (Figure 5). 
This was dependent upon the 3′ mini-hairpin structure of the 
DNA extension since a similar length DNA extension unable 
to form a hairpin offered little protection. In principle, this DNA 
extension with its mini-hairpin structure can be added to any 
double-stranded siRNA and provide protection from degra-
dation by serum nucleases, as shown here for SIRT1 siRNA, 
for JNK2 siRNA and for HPV E7 siRNA (Figure 5). Overall, 
these observations identify the 19 nt DNA sequence with its 
3′-mini-hairpin structure employed in this study as a novel 
siRNA modification with promise for overcoming problems 
associated synthetic siRNA stability in vivo and which may 
thereby aid the development of siRNA therapeutics.
From a manufacturing viewpoint, we predict that sim-
ply extending the 3′-end of synthetic siRNA with a defined 
DNA sequence (as employed in this work) will be more 
 cost-effective compared with the production of chemically 
modified RNA for therapeutic use. The former simply requires 
3′-DNA/siRNA synthesis, followed by purification to the level 
required for therapeutic application. In contrast, chemically 
modified siRNA involves siRNA synthesis, followed by purifi-
cation, followed by chemical modification and finally followed 
by repurification to the level of purity required for therapeutic 
purposes.
This is a tightly controlled multi-parameter study with 
(i) molecular, biochemical and cellular readouts, (ii) compar-
ison of human cancer versus noncancer cells, and (iii) an 
experimental model operated under basal conditions (i.e., 
without activating intrinsic cellular stress responses as occurs 
with shRNA and other silencing agents). We have performed 
 in-depth testing of a series of 3′DNA/siRNA constructs 
which, although derivative, are novel. These novel constructs 
carry advantages for (i) their recovery and quantification 
from cells and tissues; (ii) efficacy under basal conditions, 
with no apparent adverse effects on normal cells; (iii) in 
the case of SIRT1 and JNK2 siRNA constructs the cancer-
specific induction of apoptosis; and (iv) resistance to serum 
nucleases. The novel constructs may also serve as useful 
tools for further experimentation aimed at unravelling the 
mechanism of RNAi in mammalian cells. In conclusion, we 
propose that 3′-DNA/siRNA constructs offer an exciting new 
approach for (i) the therapeutic development of novel siRNAs 
with ease of manufacture and quantification, coupled with 
(ii) benefits of nuclease resistance and (iii) efficient targeted 
knock-down of disease-related targets.
Materials and methods
3′-DNA/siRNA constructs and siRNAs. In order to selec-
tively knock-down full-length SIRT1 mRNA and not that of 
its splice variants, it is necessary for the siRNA to target a 
nucleotide sequence within exon 8 of SIRT1 mRNA.20,27,34
 
We have designed two independent SIRT1 siRNAs tar-
geted against discrete RNA sequences within SIRT1-Exon 
8. Both siRNAs give equivalent and selective knock-down 
of human SIRT1 mRNA.20 For the purposes of the pres-
ent study, we selected one of these well-validated siRNAs, 
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which is targeted against nts 1550–1568 in exon 8 of human 
SIRT1 (NM_012238): SIRT1 siRNA guide strand sequence 
 5′-UACAGGGUUACAGCAAAGU(dTdT)-3′; SIRT1 siRNA 
passenger strand sequence  5′-ACUUUGCUGUAACCC 
UGUA(dTdT)-3′.20 The  3′-DNA/SIRT1 siRNA constructs 
have the same RNA sequence as the SIRT1 siRNA but dif-
fer in the 3′ addition of a 19 nucleotide DNA extension in 
place of a 3′-dTdT overhang. This DNA extension (5′-tcacct 
catcccgcgaagc-3′) forms a 3′-nuclease resistant DNA hair-
pin and can function as a DNA primer for PCR amplification 
enabling quantification of the  3′-DNA/siRNA constructs.12 
The 3′-DNA/SIRT1 siRNA constructs were chemically syn-
thesized 3′ to 5′, HPLC-purified and annealed as appropriate 
(Biospring, Frankfurt, Germany). The organization of each 
construct is outlined schematically in Figure 1a. Unmodi-
fied SIRT1 siRNA was included as a control throughout all 
experiments.
For the experiments shown in Figure 5, additional  3′-DNA/
siRNA constructs directed against other mRNA targets were 
tested and compared with unmodified siRNA. mRNA tar-
gets chosen were JNK2, silencing of which has also been 
shown to induce apoptosis in HCT116 cancer cells,25 and 
HPV16 E7. Unmodified JNK2 siRNA and HPV16 E7 siRNA 
were as previously published.12,18,25 For JNK2 siRNA, the 
effect of the 19 nucleotide DNA extension on the 3′ end of 
the siRNA guide strand was tested. This construct is des-
ignated  3′-DNA/JNK2 siRNA construct I (JNK2 I) as it is 
equivalent to  3′-DNA/SIRT1 siRNA construct I except for the 
siRNA sequence. For E7, the effect of the 19 nucleotide DNA 
extension on the 3′ end of either the guide or the passen-
ger siRNA strand was tested (3′-DNA/E7 siRNA constructs 
I and II respectively (E7 I and E7 II)). For SIRT1 siRNA, the 
effects of a different 19 nucleotide DNA extension (5′-tcacct-
catccggccaagc-3′) that is unable to form a mini-hairpin 
structure17 was tested on the 3′ end of the guide strand; this 
is designated  3′-DNA/SIRT1 siRNA construct Im (altered 
bases indicated in red). Additional unmodified siRNAs 
were Foxo4 (guide sequence 5′-GGUCCACAUAUCGGC 
UUCU(dTdT)-3′; passenger sequence 5′-AGAAGCCGAU 
AUGUGGACC (dTdT)-3′),20 SIRT1-∆Exon8 (guide sequence 
 5′-UACUGAUUACUUGGAAUUA(dTdT)-3′; passenger seq-
uence 5′-UAAUUCCAAGUAAUCAGUA(dTdT)-3′),27 lamin A/C 
(guide sequence  5′-UGUUCUUCUGGAAGUCCAG(dTdT)-3′; 
passenger sequence 5′-CUGGACUUCCAGAAGAACA 
(dTdT)-3′).20 All unmodified siRNAs have previously been 
extensively verified in human cells in vitro.20,27
Cell lines and culture. Cell lines were maintained at low pas-
sage and cultured in antibiotic-free media. HCT116 human 
colorectal epithelial cancer cells35 were cultured in Dulbecco’s 
modified Eagle medium (DMEM) with 10% fetal calf serum. 
ARPE19 cells are a human noncancer retinal epithelial cell 
line36 that senesce after prolonged passage (>8 passages). 
They can be induced to undergo neuronal transdifferentia-
tion by the retinoic acid analogue fenretinide.37 ARPE19 cells 
were cultured in DMEM-F12 with 10% fetal calf serum.
Transfection of 3′-DNA/siRNA constructs. Twenty-four hours 
prior to transfection, cells were seeded in six-well plates 
at a cell density of 6 × 104 cells (ARPE19) or 1.2 × 105 cells 
(HCT116) per well. Cells were transfected with 3′-DNA/siRNA 
constructs or control siRNAs formulated into liposomes (Oli-
gofectamine, Invitrogen, Carlsbad, CA) as described.12,23–25 
All siRNAs and 3′-DNA/siRNA constructs were initially used 
at a concentration of 100 nmol/l except for the DNA/siRNA 
construct dilution series (Figure 4; 10 point 2-fold dilution 
series; 100 nmol/l to 195 pmol/l and for Figure 5 siRNA and 
3′-DNA/siRNA starting concentration in serum of 20 nmol/l). 
The phenotypic effects shown in Figures 1–3 are for trans-
fections at 100 nmol/l. Please note that similar phenotypic 
effects were observed down to 3 nmol/l for  guide-3′-DNA/
ds SIRT1 siRNA; down to 6 nmol/l for passenger-3′-DNA/ds 
SIRT1 siRNA; and down to 12.5 nmol/l for guide-3′-DNA/ss 
SIRT1 siRNA (data not shown).
Quantification of mRNA knock-down. Total RNA was iso-
lated from cells using an RNeasy kit (Qiagen) and quan-
titated by UV spectroscopy (GeneSpecV), as previously 
described.24 For quantitative real-time RT-PCR, 50 ng total 
RNA was used per reaction. Reactions were run in quadru-
plicate using Quantitect SYBRGreen RT-PCR kit (Qiagen) 
on a DNA Engine Opticon2 system. For quantification of full-
length SIRT1 mRNA, primers  5′-CTAATTCCAAGTTCCATA 
CCC-3′ (NM_012238, nts 1401–1421, exons 7/8 boundary) 
and 5′-CTGAAGAATCTGGTGGTGAAG-3′ (NM_012238, 
nts 1704-1684, exon 8) were used. These primers are spe-
cific for full-length SIRT1 mRNA and do not amplify splice 
variant SIRT1-∆Exon8 mRNA due to their location within 
exon 8.27 Cycling conditions were 50 °C for 30 minutes, 
94 °C for 15 minutes, followed by 36 cycles of 94 °C for 30 
seconds, 55 °C for 30 seconds, 72 °C for 30 seconds. SIRT1-
∆Exon8 specific primers were  5′-ACTGTGAAGCTGTA 
CGAGGAG-3′ (NM_012238, nts 1189–1209, exon 6) and 
 5′-AACAGATACTGATTACTTGGA-3′ (NM_012238, nts 1984-
1969 and 1410-1406, exons 7/9 boundary).27 Cycling condi-
tions were as for full-length SIRT1 except that the annealing 
temperature was 53 °C. For lamin A/C mRNA quantifica-
tion, primers  5′-AAGCAGCGTGAGTTTGAGAGC-3′ and 
5′-AGGGTGAACTTTGGTGGGAAC-3′ were used in the 
thermal cycle: 50 °C for 30 minutes, 94 °C for 15 minutes, 
followed by 36 cycles of 94 °C for 45 seconds, 58 °C for 45 
seconds, and 72 °C for 1 minutes.
RNA immunoprecipitation. RNA immunoprecipitations were 
performed as described38 using 10 six-well plates per 3′-
DNA/siRNA construct. Twenty-four hours after transfection, 
equivalent numbers of transfected cells were lysed using 
polysome lysis buffer (100 mmol/l KCl, 5 mmol/l MgCl2, 10 
mmol/l Hepes pH 7, 0.5% NP40, 1 mmol/l DTT, 100 U/ml 
RNase inhibitor, 2 mmol/l vanadyl ribonucleoside complexes 
solution, 25 µl/ml protease inhibitor cocktail (Sigma, St Louis, 
MO)). Following centrifugation at 16000g for 15 minutes at 
4 °C, an aliquot of supernatant was removed for determina-
tion of the starting amount of SIRT1 mRNA in each immuno-
precipitation reaction. The residual supernatant was divided 
equally into two, and incubated overnight at 4 °C with 5 µg of 
anti-Ago2 antibody (clone 9E8.2 RIPAb+, Millipore) or 5 µg of 
normal mouse IgG (Millipore). Protein-RNA complexes were 
collected on protein A/G agarose beads for 3 hours at 4 °C, fol-
lowed by eight washes with polysome lysis buffer. One-tenth 
www.moleculartherapy.org/mtna
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of the slurry of washed beads was added to 2xLaemmli’s SDS 
buffer for immunoblotting. The remaining beads were resus-
pended in polysome lysis buffer containing 0.5% SDS and 
30 µg proteinase K and incubated at 50 °C for 30 minutes to 
elute any immunoprecipitated RNA. RNA was extracted once 
with phenol-chloroform-isoamyl alcohol (25:24:1) and once 
with chloroform-isoamyl alcohol (24:1), and then precipitated 
with 2.5 vol ice-cold 100% ethanol in the presence of 1 µl gly-
coblue (Ambion). Purified RNA from the immunoprecipitation 
reactions, and inputs were analyzed for SIRT1 mRNA levels 
by quantitative real-time RT-PCR. For quantification of intact, 
uncleaved full-length SIRT1 mRNA, primers 5′-CTAATTC 
CAAGTTCCATACCC-3′ (NM_012238, nts 1401–1421, exons 
7/8 boundary) and 5′-CTGAAGAATCTGGTGGTGAAG-3′ 
(NM_012238, nts 1704-1684, exon 8) were used.
Statistical analysis and calculation of IC50 values. Statisti-
cal analysis for Figure 3 was carried out using a two-tailed 
Student’s t-test calculated with Excel. A P value of <0.05 
was considered statistically significant. IC50 values repre-
senting the concentration of 3′-DNA/SIRT1 siRNA construct 
or unmodified SIRT1 siRNA that gives 50% knock-down of 
SIRT1 mRNA were calculated from the titration data of Fig-
ure 4 (qRT-PCR measurements for SIRT1 mRNA in quadru-
plicate normalized to lamin A/C mRNA for each concentration 
of 3′-DNA/siRNA (10 point 2-fold dilution series; 100 nmol/l to 
195 pmol/l)). The formula used to calculate the IC50 values 
is, IC50 = ((a/b) × concentration at a) + concentration at a. 
a = % of SIRT1 mRNA obtained at a particular concentration 
of 3′-DNA/siRNA that is nearest to and just above 50% – 50; 
b= % of SIRT1 mRNA obtained at a particular concentration 
of 3′-DNA/siRNA that is nearest to and just above 50% to 
% of SIRT1 mRNA obtained at a particular concentration of 
 3′-DNA/siRNA that is nearest to and just below 50%.
Immunoblotting. Total cell extracts were prepared39 and 
equivalent protein amounts were resolved by SDS-PAGE and 
electroblotted onto nitrocellulose for immunoblotting. Primary 
antibodies were anti-SIRT1 (H300; Santa Cruz, Santa Cruz, 
CA), anti-p53 (DO1; Santa Cruz), anti-K382 acetylated p53 
(Cell Signalling Technology), anti-S15 phosphorylated p53 
(Cell Signalling Technology), anti-eIF6 (Cell Signalling Tech-
nology), anti-actin (Chemicon), and C3PO antibody.7 Visual-
ization of bound antibodies was by ECL.
Apoptosis. Apoptotic cells were identified and quantified by 
flow cytometry and annexin V/propidium iodide labeling using 
annexin-V-Fluos kit (Roche, Basel, Switzerland) following the 
manufacturer’s protocol.24
Gel electrophoresis analysis of 3′-DNA/siRNA constructs. 
For the experiments shown in Figure 5, equivalent amounts 
of 3′-DNA/siRNA constructs or unmodified siRNAs were 
preincubated in 5% serum or no serum for 16 hours at 37 
°C before then either being used for transfection (starting 
concentration assuming no degradation of 20 nmol/l) or ana-
lyzed by gel electrophoresis. For gel electrophoresis, sam-
ples were run on a 2% agarose-1xTAE gel at 90 V for 30 
minutes and visualized either by ethidium bromide staining 
or, for the single-stranded siRNAs and constructs, by SYBR 
Gold staining. Quantification of band intensities by densitom-
etry was performed using Quantity One software (Biorad).
Supplementary material
Figure S1. siRNA/DNA oligonucleotide sequences of 
 constructs.
Acknowledgments. This work was supported in part by 
C2D2, Funder grant number: 097829/Z/11/A, York grant 
number: A0119732, and in part by a Yorkshire Cancer Re-
search core research funding award to J.M. C3PO antibody 
was a generous gift from Professor Qinghua Liu (Southwest-
ern Medical Centre, University of Texas). The authors declare 
no conflict of interest.
1. Siomi, H and Siomi, MC (2009). On the road to reading the RNA-interference code. Nature 
457: 396–404.
2. Carthew, RW and Sontheimer, EJ (2009). Origins and Mechanisms of miRNAs and 
siRNAs. Cell 136: 642–655.
3. Liu, J, Carmell, MA, Rivas, FV, Marsden, CG, Thomson, JM, Song, JJ et al. (2004). 
Argonaute2 is the catalytic engine of mammalian RNAi. Science 305: 1437–1441.
4. Song, JJ, Smith, SK, Hannon, GJ and Joshua-Tor, L (2004). Crystal structure of Argonaute 
and its implications for RISC slicer activity. Science 305: 1434–1437.
5. Rivas, FV, Tolia, NH, Song, JJ, Aragon, JP, Liu, J, Hannon, GJ et al. (2005). Purified 
Argonaute2 and an siRNA form recombinant human RISC. Nat Struct Mol Biol 12: 
340–349.
6. Kim, K, Lee, YS and Carthew, RW (2007). Conversion of pre-RISC to holo-RISC by Ago2 
during assembly of RNAi complexes. RNA 13: 22–29.
7. Liu, Y, Ye, X, Jiang, F, Liang, C, Chen, D, Peng, J et al. (2009). C3PO, an 
endoribonuclease that promotes RNAi by facilitating RISC activation. Science 325: 
750–753.
8. Ye, X, Huang, N, Liu, Y, Paroo, Z, Huerta, C, Li, P et al. (2011). Structure of C3PO and 
mechanism of human RISC activation. Nat Struct Mol Biol 18: 650–657.
9. Rao, DD, Vorhies, JS, Senzer, N and Nemunaitis, J (2009). siRNA vs. shRNA: similarities 
and differences. Adv Drug Deliv Rev 61: 746–759.
10. Castanotto, D and Rossi, JJ (2009). The promises and pitfalls of RNA-interference-based 
therapeutics. Nature 457: 426–433.
11. Burnett, JC, Rossi, JJ and Tiemann, K (2011). Current progress of siRNA/shRNA 
therapeutics in clinical trials. Biotechnol J 6: 1130–1146.
12. Jiang, M, Arzumanov, AA, Gait, MJ and Milner, J (2005). A bi-functional siRNA construct 
induces RNA interference and also primes PCR amplification for its own quantification. 
Nucleic Acids Res 33: e151.
13. Hirao, I, Nishimura, Y, Tagawa, Y, Watanabe, K and Miura, K (1992). Extraordinarily stable 
mini-hairpins: electrophoretical and thermal properties of the various sequence variants of 
d(GCGAAAGC) and their effect on DNA sequencing. Nucleic Acids Res 20: 3891–3896.
14. Khan, IM and Coulson, JM (1993). A novel method to stabilise antisense oligonucleotides 
against exonuclease degradation. Nucleic Acids Res 21: 2957–2958.
15. Yoshizawa, S, Ueda, T, Ishido, Y, Miura, K, Watanabe, K and Hirao, I (1994). Nuclease 
resistance of an extraordinarily thermostable mini-hairpin DNA fragment, d(GCGAAGC) 
and its application to in vitro protein synthesis. Nucleic Acids Res 22: 2217–2221.
16. Réfrégiers, M, Laigle, A, Jollès, B and Chinsky, L (1996). Fluorescence resonance energy 
transfer analysis of the degradation of an oligonucleotide protected by a very stable 
hairpin. J Biomol Struct Dyn 14: 365–371.
17. Jollès, B, Réfrégiers, M and Laigle, A (1997). Opening of the extraordinarily stable  mini-
hairpin d(GCGAAGC). Nucleic Acids Res 25: 4608–4613.
18. Jiang, M and Milner, J (2002). Selective silencing of viral gene expression in HPV-positive 
human cervical carcinoma cells treated with siRNA, a primer of RNA interference. 
Oncogene 21: 6041–6048.
19. Haigis, MC and Sinclair, DA (2010). Mammalian sirtuins: biological insights and disease 
relevance. Annu Rev Pathol 5: 253–295.
20. Ford, J, Jiang, M and Milner, J (2005). Cancer-specific functions of SIRT1 enable human 
epithelial cancer cell growth and survival. Cancer Res 65: 10457–10463.
21. Knight, JR and Milner, J (2012). SIRT1, metabolism and cancer. Curr Opin Oncol 24: 
68–75.
22. Beckerman, R and Prives, C (2010). Transcriptional regulation by p53. Cold Spring Harb 
Perspect Biol 2: a000935.
23. Jiang, M and Milner, J (2003). Bcl-2 constitutively suppresses p53-dependent apoptosis in 
colorectal cancer cells. Genes Dev 17: 832–837.
24. Allison, SJ and Milner, J (2007). SIRT3 is pro-apoptotic and participates in distinct basal 
apoptotic pathways. Cell Cycle 6: 2669–2677.
25. Ahmed, SU and Milner, J (2009). Basal cancer cell survival involves JNK2 suppression of 
a novel JNK1/c-Jun/Bcl-3 apoptotic network. PLoS ONE 4: e7305.
Molecular Therapy—Nucleic Acids
RNA Interference by 3′-DNA/siRNA Oligonucleotides
Allison and Milner
12
26. Chendrimada, TP, Finn, KJ, Ji, X, Baillat, D, Gregory, RI, Liebhaber, SA et al. (2007). 
MicroRNA silencing through RISC recruitment of eIF6. Nature 447: 823–828.
27. Lynch, CJ, Shah, ZH, Allison, SJ, Ahmed, SU, Ford, J, Warnock, LJ et al. (2010). SIRT1 
undergoes alternative splicing in a novel auto-regulatory loop with p53. PLoS ONE 5: 
e13502.
28. Vickers, TA, Koo, S, Bennett, CF, Crooke, ST, Dean, NM and Baker, BF (2003). Efficient 
reduction of target RNAs by small interfering RNA and RNase H-dependent antisense 
agents. A comparative analysis. J Biol Chem 278: 7108–7118.
29. Wang, Y, Sheng, G, Juranek, S, Tuschl, T and Patel, DJ (2008). Structure of the  guide-
strand-containing argonaute silencing complex. Nature 456: 209–213.
30. Wang, Y, Juranek, S, Li, H, Sheng, G, Tuschl, T and Patel, DJ (2008). Structure of an 
argonaute silencing complex with a seed-containing guide DNA and target RNA duplex. 
Nature 456: 921–926.
31. Wang, Y, Juranek, S, Li, H, Sheng, G, Wardle, GS, Tuschl, T et al. (2009). Nucleation, 
propagation and cleavage of target RNAs in Ago silencing complexes. Nature 461: 
754–761.
32. Parker, JS (2010). How to slice: snapshots of Argonaute in action. Silence 1: 3.
33. Haringsma, HJ, Li, JJ, Soriano, F, Kenski, DM, Flanagan, WM and Willingham, AT (2012). 
mRNA knockdown by single strand RNA is improved by chemical modifications. Nucleic 
Acids Res 40: 4125–4136.
34. Shah, ZH, Ahmed, SU, Ford, JR, Allison, SJ, Knight, JR and Milner, J (2012). A 
deacetylase-deficient SIRT1 variant opposes full-length SIRT1 in regulating tumor 
suppressor p53 and governs expression of cancer-related genes. Mol Cell Biol 32: 
704–716.
35. Bunz, F, Dutriaux, A, Lengauer, C, Waldman, T, Zhou, S, Brown, JP et al. (1998). 
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 
1497–1501.
36. Dunn, KC, Aotaki-Keen, AE, Putkey, FR and Hjelmeland, LM (1996). ARPE-19, a human 
retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 62: 155–169.
37. Chen, S, Samuel, W, Fariss, RN, Duncan, T, Kutty, RK and Wiggert, B (2003). 
Differentiation of human retinal pigment epithelial cells into neuronal phenotype by  
N-(4-hydroxyphenyl)retinamide. J Neurochem 84: 972–981.
38. Peritz, T, Zeng, F, Kannanayakal, TJ, Kilk, K, Eiríksdóttir, E, Langel, U et al. (2006). 
Immunoprecipitation of mRNA-protein complexes. Nat Protoc 1: 577–580.
39. Ford, J, Ahmed, S, Allison, S, Jiang, M and Milner, J (2008). JNK2-dependent regulation of 
SIRT1 protein stability. Cell Cycle 7: 3091–3097.
Molecular Therapy–Nucleic Acids is an open-access 
 journal published by Nature Publishing Group. This 
work is licensed under a Creative Commons Attribution 3.0 Unported 
License. To view a copy of this license, visit http://creativecommons.
org/licenses/by/3.0/ 
